Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/03000605211013550 http://scihub22266oqcxt.onion/10.1177/03000605211013550 33983065!8127799!33983065     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Int+Med+Res 2021 ; 49 (5): 3000605211013550 Nephropedia Template TP {{tp|p=33983065|t=2021. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial |pdf=|usr=}}{{33983065}} gab.com Text Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial JO: J Int Med Res http://www.kidney.de/pget.php?&tw=1&pmid=33983065 #FOAvip OBJECTIVE: We evaluated whether ivermectin combined with doxycycline reduced the clinical recovery time in adults with COVID-19 infection. METHODS: This was a randomized, blinded, placebo-controlled trial in patients with mild-to-moderate COVID-19 symptoms randomly assigned to treatment (n = 200) and placebo (n = 200) groups. The primary outcome was duration from treatment to clinical recovery. Secondary outcomes were disease progression and persistent COVID-19 positivity by RT-PCR. RESULTS: Among 556 screened patients, 400 were enrolled and 363 completed follow-up. The mean patient age was 40 years, and 59% were men. The median recovery time was 7 (4-10, treatment group) and 9 (5-12, placebo group) days (hazard ratio, 0.73; 95% confidence interval, 0.60-0.90). The number of patients with a </=7-day recovery was 61% (treatment group) and 44% (placebo groups) (hazard ratio, 0.06; 95% confidence interval, 0.04-0.09). The proportion of patients who remained RT-PCR positive on day 14 and whose disease did not progress was significantly lower in the treatment group than in the placebo group. CONCLUSIONS: Patients with mild-to-moderate COVID-19 infection treated with ivermectin plus doxycycline recovered earlier, were less likely to progress to more serious disease, and were more likely to be COVID-19 negative by RT-PCR on day 14. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04523831. DATA REPOSITORY ID: Dryad. doi:10.5061/dryad.qjq2bvqf6. Twit Text FOAVip Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial ????J Int Med Res http://www.kidney.de/pget.php?&tw=1&pmid=33983065 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33983065 #FOAvip English Wikipedia <ref>{{Cite pmid|33983065}}</ref> Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial #MMPMID33983065 Mahmud R; Rahman MM; Alam I; Ahmed KGU; Kabir AKMH; Sayeed SKJB; Rassel MA; Monayem FB; Islam MS; Islam MM; Barshan AD; Hoque MM; Mallik MU; Yusuf MA; Hossain MZ J Int Med Res 2021[May]; 49 (5): 3000605211013550 PMID33983065show ga OBJECTIVE: We evaluated whether ivermectin combined with doxycycline reduced the clinical recovery time in adults with COVID-19 infection. METHODS: This was a randomized, blinded, placebo-controlled trial in patients with mild-to-moderate COVID-19 symptoms randomly assigned to treatment (n = 200) and placebo (n = 200) groups. The primary outcome was duration from treatment to clinical recovery. Secondary outcomes were disease progression and persistent COVID-19 positivity by RT-PCR. RESULTS: Among 556 screened patients, 400 were enrolled and 363 completed follow-up. The mean patient age was 40 years, and 59% were men. The median recovery time was 7 (4-10, treatment group) and 9 (5-12, placebo group) days (hazard ratio, 0.73; 95% confidence interval, 0.60-0.90). The number of patients with a |*COVID-19[MESH] |*Ivermectin/therapeutic use[MESH] |Adult[MESH] |Doxycycline/therapeutic use[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |SARS-CoV-2[MESH]Ivermectin in combination with doxycycline for treating COVID-19 sympt(epmc).pdf DeepDyve Pubget Overpricing